Old Web
English
Sign In
Acemap
>
authorDetail
>
Mitchell L. Henry
Mitchell L. Henry
The Ohio State University Wexner Medical Center
Calcineurin
Medicine
Everolimus
Mycophenolic acid
Clinical trial
3
Papers
5
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study.
2021
BMJ Open
Olivier Aubert
Gillian Divard
Julio Pascual
Federico Oppenheimer
Claudia Sommerer
Franco Citterio
H. Tedesco
Steve Chadban
Mitchell L. Henry
Flavio Vincenti
Titte Srinivas
Yoshihiko Watarai
Christophe Legendre
Peter Bernhardt
Alexandre Loupy
Show All
Source
Cite
Save
Citations (0)
Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: Insights from the 24 month TRANSFORM study.
2020
Expert Opinion on Drug Safety
Franco Citterio
Mitchell L. Henry
Dean Y. Kim
Myoung Soo Kim
Duck-Jong Han
Takashi Kenmochi
Eytan Mor
Giuseppe Tisone
Peter Bernhardt
Maria Pilar Hernandez Gutierrez
Yoshihiko Watarai
Show All
Source
Cite
Save
Citations (0)
Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients
2019
Transplantation Reviews
Julio Pascual
Stefan P. Berger
Steven J. Chadban
Franco Citterio
Nassim Kamar
Dennis A. Hesselink
Christophe Legendre
Ute Eisenberger
Federico Oppenheimer
Graeme R. Russ
Claudia Sommerer
Paolo Rigotti
Titte R. Srinivas
Yoshihiko Watarai
Mitchell L. Henry
Flavio Vincenti
Helio Tedesco Silva
Show All
Source
Cite
Save
Citations (5)
1